Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity (Q46894623)

26 December 2017

title

Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity (English)

1 reference

26 December 2017

author name string

R Rieger

1 reference

26 December 2017

D Whitacre

1 reference

26 December 2017

M J Cantwell

1 reference

26 December 2017

C Prussak

1 reference

26 December 2017

T J Kipps

1 reference

26 December 2017

publication date

25 July 2008

1 reference

26 December 2017

published in

Cancer Gene Therapy

1 reference

26 December 2017

volume

1 reference

26 December 2017

issue

1 reference

26 December 2017

page(s)

53-64

1 reference

26 December 2017

An endotoxin-induced serum factor that causes necrosis of tumors

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Tumour necrosis factor in man: clinical and biological observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Generation and Biological Characterization of Membrane-bound, Uncleavable Murine Tumor Necrosis Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Comparison of in vitro cell cytotoxic assays for tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Cleavage of membrane-bound CD40 ligand is not required for inducing B cell proliferation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Tumor necrosis factor, cancer and anticancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

TNF-R1 signaling: a beautiful pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Tumor necrosis factor receptor superfamily members and their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Toxicity and morbidity of isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Characterisation of functional biotinylated TNF-alpha targeted to the membrane of apoptotic melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Selective targeted delivery of TNFalpha to tumor blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

TNF alpha and the TNF receptor superfamily: structure-function relationship(s).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Studies on the use of viruses in the treatment of carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

Tumor immunity and prolonged survival following combined adenovirus-HSP72 and CEA-plasmid vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.57

TNF receptor distribution in human tissues

21 January 2018

1 reference

12 December 2020

Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity

1 reference

12 December 2020

Phase I study of recombinant tumor necrosis factor in cancer patients.

1 reference

12 December 2020

Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha

1 reference

12 December 2020

Clinical studies with tumour necrosis factor.

1 reference

12 December 2020

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

1 reference

12 December 2020

A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation

1 reference

12 December 2020

Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization

1 reference

12 December 2020

Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells

1 reference

12 December 2020

Toxic effect of tumor necrosis factor on tumor vasculature in mice

1 reference

12 December 2020

Identifiers

DOI

10.1038/CGT.2008.57

1 reference

26 December 2017

1 reference

26 December 2017